Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Why Invest
Ironwood Is Leading In
GI
Through
G
rowth And
I
nnovation
Leading position in the IBS-C / CIC market that exceeded $1 billion in 2021 LINZESS U.S. net sales, with continued strong prescription demand growth potential
Highly capable commercial team with deep GI experience across the U.S. with leading GI specialists and PCPs
Actively pursuing opportunities to strengthen innovative pipeline of GI assets in areas of high unmet need
Exploring linaclotide Lifecycle Management opportunities with potential pediatric FC indication in 6-17 year-olds in 2023
Strong balance sheet and cash flows enables disciplined capital allocation to reach new patients and to deliver value to shareholders
Accomplished management team with strong GI commercial, drug development and M&A expertise
Our Strategy:
Maximize LINZESS
Strengthen and Progress Innovative GI Portfolio
Deliver Sustained Profits and Generate Cash Flow